methyl 1-(phenylsulfonyl)piperidine-4-carboxylate | 311794-15-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 1-(phenylsulfonyl)piperidine-4-carboxylate
• 英文别名: 1-benzenesulfonyl-piperidine-4-carboxylic acid methyl ester；1-Benzolsulfonyl-piperidin-4-carbonsaeure-methylester；Methyl 1-(phenylsulfonyl)-4-piperidinecarboxylate；methyl 1-(benzenesulfonyl)piperidine-4-carboxylate
• CAS: 311794-15-7
• 化学式: C₁₃H₁₇NO₄S
• mdl: MFCD01045646
• 分子量: 283.348
• InChiKey: PFLNGTSVVWOTQA-UHFFFAOYSA-N

物化性质

• 熔点：
  83-85°C
• 沸点：
  410.3±55.0 °C(Predicted)
• 密度：
  1.274±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  methyl 1-(phenylsulfonyl)piperidine-4-carboxylate 在 甲醇 、 肼 作用下， 生成 1-(phenylsulfonyl)piperidine-4-carbohydrazide
  参考文献：
  名称：

  Spiro-1'-benzenesulfonylpiperidine-4',5-barbituric Acid and Related Derivatives of Isonipecotic Acid

  摘要：

  DOI：

  10.1021/ja01613a067
• 作为产物：
  描述：

  1-benzenesulfonyl-piperidine-4,4-dicarboxylic acid diethyl ester 在 sodium hydroxide 、 氯化亚砜 作用下， 生成 methyl 1-(phenylsulfonyl)piperidine-4-carboxylate
  参考文献：
  名称：

  Spiro-1'-benzenesulfonylpiperidine-4',5-barbituric Acid and Related Derivatives of Isonipecotic Acid

  摘要：

  DOI：

  10.1021/ja01613a067

文献信息

• One-Pot Synthesis of Homoallylic Ketones from the Addition of Vinyl Grignard Reagent to Carboxylic Esters
  作者：Karl A. Hansford、James E. Dettwiler、William D. Lubell

  DOI：10.1021/ol0359822

  日期：2003.12.1

  Fifteen homoallylic ketones have been synthesized in 26-77% yields on treatment of aromatic, aliphatic, and alpha-amino methyl carboxylates with excess vinylmagnesium bromide and catalytic amounts of a copper salt in THF. Alpha-amino homoallylic ketones derived from N-protected alpha-amino esters possessing aliphatic and alcohol side chains were synthesized in > or =98% enantiomeric purity. [reaction:

  在用过量的乙烯基溴化镁和催化量的铜盐在THF中处理芳族，脂肪族和α-氨基甲基羧酸盐后，已以26-77％的产率合成了15个均烯丙基酮。衍生自具有脂肪族和醇侧链的N-保护的α-氨基酯衍生的α-氨基均烯丙基酮，其对映体纯度> 98％或= 98％。[反应：看文字]
• [EN] DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER<br/>[FR] DÉRIVÉS DE PYRROLOIMIDAZOLE OU ANALOGUES DE CEUX-CI UTILES, ENTRE AUTRES, DANS LE TRAITEMENT DU CANCER
  申请人：EMCURE PHARMACEUTICALS LTD

  公开号：WO2017134555A1

  公开（公告）日：2017-08-10

  Present invention relates to novel heterocyclic compounds as indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) modulators. Compounds of the present invention inhibit tryptophan degradation by modulating IDO and/or TDO. Formula (I) The invention further relates to the process of their preparation, pharmaceutical composition and their use in modulating the activity of indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3- dioxygenase (TDO). The compounds of the invention can be used alone or in combination for the treatment of conditions that benefits from the inhibition of tryptophan degradation.

  本发明涉及作为吲哚胺2,3-二氧化酶（IDO）和/或色氨酸2,3-二氧化酶（TDO）调节剂的新型杂环化合物。本发明的化合物通过调节IDO和/或TDO来抑制色氨酸降解。公式（I）。本发明还涉及它们的制备过程、药物组合物及其在调节吲哚胺2,3-二氧化酶（IDO）和/或色氨酸2,3-二氧化酶（TDO）活性中的应用。本发明的化合物可以单独使用或与其他药物组合用于治疗受益于抑制色氨酸降解的疾病。
• DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM
  申请人：OHTA Toshiharu

  公开号：US20090281074A1

  公开（公告）日：2009-11-12

  Drug compositions containing a substituted diamine compound represented by formula (1): Q 1 -Q 2 -r-N(R 1 )-Q 3 -N(R 2 )  (1) wherein Q 3 represents the following group wherein Q 5 represents an alkylene group having 4 carbon atoms, R 3 represents a hydrogen atom, and R 4 represents a 3-6 membered heterocyclic group which may be substituted; are useful for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

  含有以下式子（1）所代表的取代二胺化合物的药物组合物： Q1-Q2-r-N（R1）-Q3-N（R2）  （1） 其中，Q3代表以下基团： 其中，Q5代表具有4个碳原子的烷基基团，R3代表氢原子，R4代表可取代的3-6环杂环基团； 该药物组合物对于预防和/或治疗脑梗死、脑栓塞、心肌梗死、心绞痛、肺梗死、肺栓塞、布尔格病、深静脉血栓形成、弥散性血管内凝血综合征、人工瓣膜或关节置换后的血栓形成、血管成形术后的血栓形成和再闭塞、全身性炎症反应综合征（SIRS）、多器官功能障碍综合征（MODS）、体外循环期间的血栓形成或采血时的血凝。
• METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES
  申请人：Ohta Toshiharu

  公开号：US20100099660A1

  公开（公告）日：2010-04-22

  A method for treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing is provided. The method includes administration of an effective amount of a compound represented by formula (1):

  提供了一种治疗脑梗塞、脑栓塞、心肌梗死、心绞痛、肺梗塞、肺栓塞、布尔格病、深静脉血栓形成、弥散性血管内凝血综合征、人工瓣膜或关节置换后的血栓形成、血管成形术后的血栓形成和再闭塞、多器官功能障碍综合征（MODS）、体外循环期间的血栓形成或采血时的血液凝固的方法。该方法包括给予化合物（1）式所代表的有效量。
• Novel ethylenediamine derivatives
  申请人：Nakamoto Yumi

  公开号：US20070129371A1

  公开（公告）日：2007-06-07

  A compound represented by the following formula (1): Q 1 —Q 2 —T o —N(R 1 )—Q 3 —N(R 2 )—T 1 —Q 4 ( 1 ) [wherein, R 1 and R 2 are hydrogen atoms or the like; Q 1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may have a substituent, or the like; Q 2 is a single bond or the like; Q 3 represents the following group: —C(R 3a )(R 4a )—C(R 3b )(R 4b )}m 1 —C(R 3c )(R 4c )}m 2 —C(R 3d )(R 4d )}m 3 —C(R 3e )(R 4e )}m 4 —C (R 3f )(R 4f )— (in which, R 3a to R 4e represent hydrogen or the like); T 0 represents a carbonyl group or the like; and T 1 represents —COCONR— or the like]; or salt thereof, solvate thereof, or N-oxide thereof. The compound is useful as a preventive and/or therapeutic agent for cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

  以下化合物公式（1）表示的化合物：Q1-Q2-To-N（R1）-Q3-N（R2）-T1-Q4（1）[其中，R1和R2是氢原子或类似物；Q1是饱和或不饱和的5或6元环烃基，可以具有取代基或类似物；Q2是单键或类似物；Q3表示以下基团：-C（R3a）（R4a）-C（R3b）（R4b）}m1-C（R3c）（R4c）}m2-C（R3d）（R4d）}m3-C（R3e）（R4e）}m4-C（R3f）（R4f）-（其中，R3a到R4e代表氢或类似物）；T0表示羰基基团或类似物；T1表示-COCONR-或类似物]；或其盐，溶剂化合物或N-氧化物。该化合物可用作预防和/或治疗脑梗死、脑栓塞、心肌梗死、心绞痛、肺梗死、肺栓塞、布尔格病、深静脉血栓形成、弥漫性血管内凝血综合征、瓣膜或关节置换后的血栓形成、血管成形术后的血栓形成和再闭塞、全身性炎症反应综合征（SIRS）、多器官功能障碍综合征（MODS）、体外循环期间的血栓形成或采血时的血液凝固。